30
Participants
Start Date
October 8, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
June 30, 2027
CT011 CAR-GPC3 T Cells Injection
The dose selection for this trial was mainly based on the preliminary safety and efficacy results of CT011-HCC-01 trial in subjects with advanced HCC, in which 3 and 5 subjects in the 2.5 × 108 cell and 5.0 × 108 cell dose groups, respectively, completed a single infusion of CT011. The results showed that the two dose groups of CT011 were generally well tolerated in HCC subjects who failed to standard treatment, with controllable safety, and showed preliminary anti-tumor efficacy.
RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
RECRUITING
Hunan Provincial People's Hospital, Changsha
RECRUITING
Sichuan Cancer Hospital, Chengdu
RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Chongqing university ca cer hospital, Chongqing
RECRUITING
Mengchao hepatobiliary hospital of fujian medical university, Fuzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guanzhou
RECRUITING
Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou
RECRUITING
The second affiliated hospital zhejiang university school of medicine, Hangzhou
RECRUITING
Zhongshan Hospital Fudan University, Shanghai
RECRUITING
Liaoning Cancer Hospital, Shenyang
RECRUITING
The first hospital of china medical university, Shenyang
RECRUITING
Tianjin medical university cancer hospital, Tianjin
RECRUITING
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan
RECRUITING
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Lead Sponsor
Shanghai Zhongshan Hospital
OTHER
CARsgen Therapeutics Co., Ltd.
INDUSTRY